Vascular cognitive impairment

Current Treatment Options in Cardiovascular Medicine

Volumn 8, Issue 3, 2006, Pages 243-250

  Pedelty, Laura ^a   Nyenhuis, David L ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; RIVASTIGMINE; TACRINE; WARFARIN; XANTHINE DERIVATIVE;

ABDOMINAL PAIN; AGITATION; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; ATAXIA; BRADYCARDIA; BRAIN HEMORRHAGE; BRAIN INFARCTION; CARDIOTOXICITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EARLY DIAGNOSIS; ENZYME INHIBITION; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; GRAY MATTER; HEADACHE; HEART ATRIUM FIBRILLATION; HEART BLOCK; HOSPITALIZATION; HUMAN; HYPERTENSION; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PERMISSIBLE DOSE; MEMORY DISORDER; META ANALYSIS; MULTIINFARCT DEMENTIA; NAUSEA; NEUROIMAGING; NEUROTOXICITY; PATHOGENESIS; PRIMARY PREVENTION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RISK FACTOR; RISK MANAGEMENT; SECONDARY PREVENTION; SHORT TERM MEMORY; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING; WHITE MATTER;

EID: 33646777134     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-006-0018-6     Document Type: Article

References (55)

1. Hachinski VC, Lassen NA, Marshall J: Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1974, 2:207-210.
2. Knopman DS, DeKoskey ST, Cummings JL, et al.: Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the Americal Academy of Neurology. Neurology 2001, 56:1143-1153.
3. Wolfson C, Wolfson DB, Asghaian M, et al.: Clinical Progression of Dementia Study Group. A re-evaluation of the duration of survival after the onset of dementia. N Engl J Med 2001, 344:1111-1116.
4. Rockwood K, Howard K, MacKnight C, Darvesh S: Spectrum of disease in vascular cognitive impairment Neuroepidemiology 1999, 18:248-254.
5. Rockwood K, Bowler JV, Erkinjuntti T, et al.: Subtypes of vascular dementia. Alzheimer Dis Assoc Disord 1999, 13(suppl 3):S59-S65.
6. Nyenhuis D, Gorelick PB: Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention, and treatment. J Am Geriatr Soc 1998, 46:1437-1448.
7. Rockwood K, Ebly E, Hachinski V, Hogan DB: Presence and treatment of vascular risk factors in vascular cognitive impairment. Arch Neurol 1997, 54:33-39.
8. Gorelick PB: Risk factors for dementia and Alzheimer's disease. Stroke 2004, 35(11 suppl 1):2620-2622.
9. Snowden DA, Greiner LH, Mortimer JA, et al.: Brain infarction and clinical expression of Alzheimer's disease. The Nun Study. JAMA 1997, 277:813-817.
10. Schneider JA, Wilson RS, Bienias J, et al.: Cerebral infarcts and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004, 62:1148-1155.
11. Caplan LR, Schmahmann JD, Kase CS, et al.: Caudate infarcts. Arch Neurol 1990, 51:133-143.
12. Anoni JM, Khateb A, Gramingna S: Chronic cognitive impairment following laterothalamic tract infarcts: a study of 9 cases. Arch Neurol 2003, 60:1439-1443.
13. Auchus A, Chen CP, Sodagar SN, et al.: Single stroke dementia: insights from 12 cases in Singapore. J Neurol Sci 2002, 203-204:85-89.
14. Corbett A, Bennett H, Kos S: Cognitive dysfunction following subcortical stroke. Arch Neurol 1994, 51:999-1007.
15. Roman GC, Erkinjuntti T, Wallin A, et al.: Subcortical ischaemic vascular dementia. Lancet Neurol 2002, 1:426-436.
16. Englund E: Neuropathology of white matter lesions on vascular cognitive impairment. Cerebrovas Dis 2002, 13:11-15.
17. Caplan LR: Binswanger' disease - revisited. Neurology 1995, 45:626-633.
18. Starkstein SE, Sabe S, Vasquez S, et al.: Neuropsychological, psychiatric, and cerebral blood flow findings in vascular dementia and Alzheimer's disease. Stroke 1996, 7:408-414.
19. Roman GC, Tatemichi TK, Erkinjuntti T, et al.: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
20. Chui HC, Victoroff JI, Margolin D, et al.: Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992, 42:473-480.
21. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Association; 1994.
22. World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. Geneva: World Health Organization; 1993.
23. Bowler JV, Hachinski V: Current criteria for vascular dementia: a critical appraisal. In Vascular Cognitive Impairment: Preventable Dementia. Edited by Bowler JV, Hachinski V. New York: Oxford University Press; 2003:1-11.
24. Wade J, Hachinski V: Revised ischemic score for diagnosing multi-infarct dementia. J Clin Psychiatry 1986, 47:437-438.
25. Maduriera S, Guerreiro M, Ferro JM: Dementia and cognitive impairment three months after stroke. Eur J Neurol 2001, 8:621-627.
26. Nyenhuis D, Gorelick PB, Geenen E, et al.: The pattern of neuropathological deficits in Vascular Cognitive Impairment, No Dementia (Vascular CIND). Clin Neuropsychol 2004, 18:41-49.
27. Goldstein LB, Adams R, Becker K, et al.: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001, 103:163-182.
28. Gorelick PB: Prevention. In Vascular Cognitive Impairment: Preventable Dementia. Edited by Bowler JV, Hachinski V. New York: Oxford University Press; 2003:309-320.
29. Forette F, Seux ML, Staessen JA, et al.: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351.
30. Tzourio C, Anderson C, Chapman N, et al.: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163:1069-1075.
31. Pandey D, Gorelick PB: Should statin agents be administered to all patients with ischemic stroke? Arch Neurol 2005, 62:23-24.
32. Darvesh S, Martin E, Walsh R, Rockwood K: Differential effects of lipid-lowering agents on human cholinesterases. Clin Biochem 2004, 37:42-49.
33. Ott A, Stolk RP, van Harskamp F, et al.: Diabetes mellitus and the risk of dementia. The Rotterdam Study. Neurology 1999, 53:1937-1942.
34. Lovestone S: Diabetes and dementia. Is the brain another site of end-organ damage? Neurology 1999, 53:1907-1909.
35. Galanis DJ, Petrovich H, Launier LJ, et al.: Smoking history in middle age and subsequent cognitive performance in elderly Japanese-American men. The Honolulu-Asia aging study. Am J Epidemiol 1997, 145:507-515.
36. Erkinjuntti T, Roman GC, Gauthier S, et al.: Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 2004, 35:1010-1017.
37. Kimura S, Saito H, Minami M, et al.: Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000, 153:167-178.
38. Gottfries CG, Blennow K, Karlssin I, et al.: The neurochemistry of vascular dementia. Dementia 1994, 5:163-167.
39. Roman GC: Facts, myths and controversies in vascular dementia. J Neurol Sci 2004, 226:49-52.
40. Wilkinson D, Doody R, Helme R, et al.: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003, 61:479-486.
41. Black S, Roman GC, Geldmacher DS, et al.: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Donepezil 307 Vascular Dementia Study Group. Stroke 2003, 34:2320-2330.
42. Moretti R, Torre P, Antomello RM, et al.: Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 2003, 18:565-572.
43. Erkinjuntti T, Kurz A, Gauthier S, et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002, 359:1283-1290.
44. Orgogozo JM, Rigaud AS, Stoffler A, et al.: Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomized, placebo-controlled trial (MMM 300). Stroke 2002, 33:1834-1839.
45. Wilcock G, Mobius HJ, Stoffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). MMM 500 Group. Int Clin Psychopharmacol 2002, 17:297-305.
46. Singer DE, Albers GW, Dalen JE, et al.: Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126:429-456.
47. Meyer JS, Rogers RL, McClintic K, et al.: Randomized clinical trial of daily aspirin in multi-infarct dementia. J Am Geriatr Soc 1989, 37:549-555.
48. Sturmer T, Glynn RJ, Field TS, et al.: Aspirin and cognitive function in the elderly. Am J Epidemiol 1996, 14:683-691.
49. A randomized trial of anticoagulants versus aspirin in cerebral ischemia.fhe Stroke Prevention in Reversible Ischemia Study Group [no authors listed]. Ann Neurol 1997, 42:857-865.
50. Kittner B: Clinical trials of propentofylline in vascular dementia. European/Canadian Propentifylline Study Group. Alzheimer Dis Assoc Disord 1999, 13(suppl 3):S166-S171.
51. Pantoni L: Treatment of vascular dementia: evidence from trials of non-cholinergic drugs. J Neurol Sci 2004, 226:67-70.
52. Chobanian A, Bakris G, Black H, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003, 289:2560-2572.
53. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2586-2497.
54. Grundy S, Cleeman J, Merz C, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004, 24:e49-e61.
55. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2005, 28(suppl 1):s4-s36.